Literature DB >> 10646485

The role of current strategies in the future treatment of rheumatoid arthritis.

M E Weinblatt1.   

Abstract

Rheumatoid arthritis (RA) is a serious, chronic, debilitating disease for which no cure is available. Therapeutic aims for patients with RA are to alleviate symptoms, slow disease progression and optimize quality of life. In recent years, measures to achieve these goals have changed, and the development of new drugs will probably result in new treatment regimens. Two drugs with an extensive record of clinical experience are methotrexate and cyclosporin. Methotrexate is widely used because of its efficacy and high therapy retention rate. Both drugs have been shown to slow the progression of RA, but not without side-effects that sometimes preclude their use. As neither drug generally induces remission, improved treatments are needed. Combination therapy using drugs with different mechanisms of action is beginning to be evaluated, as are biological response modifiers targeted to specific mediators of the immune response. The future treatment of RA should provide more effective relief with fewer side-effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10646485

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  5 in total

Review 1.  Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis.

Authors:  J S Smolen; F C Breedveld; G R Burmester; B Combe; P Emery; J R Kalden; L Klareskog; R N Maini; R Numo; L B van De Putte; P L van Riel; V Rodriguez-Valverde
Journal:  Ann Rheum Dis       Date:  2000-07       Impact factor: 19.103

2.  2-Chloroadenosine but not adenosine induces apoptosis in rheumatoid fibroblasts independently of cell surface adenosine receptor signalling.

Authors:  Masahiro Koshiba; Hidekazu Kosaka; Takashi Nakazawa; Nobuhide Hayashi; Ryuichi Saura; Noriko Kitamura; Shunichi Kumagai
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

3.  Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension.

Authors:  T K Kvien; H K Zeidler; P Hannonen; F A Wollheim; O Førre; I Hafström; J P Kaltwasser; M Leirisalo-Repo; B Manger; L Laasonen; H Prestele; P Kurki
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 4.  Understanding emerging treatment paradigms in rheumatoid arthritis.

Authors:  Ferdinand C Breedveld; Bernard Combe
Journal:  Arthritis Res Ther       Date:  2011-05-25       Impact factor: 5.156

5.  TNF-α Polymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications?

Authors:  A Scardapane; L Breda; M Lucantoni; F Chiarelli
Journal:  Int J Rheumatol       Date:  2012-10-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.